Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
New England Journal of Medicine · 26.06.2025 · 392 (24) · 2425-2437
DOI: 10.1056/nejmoa2501912 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 26.06.2025. Verfasst von Elena Elez und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Hospital Campus, Barcelona. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carbamates, Cetuximab, Colorectal Neoplasms. Die Arbeit wurde bisher 185-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Pfizer, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vall d'Hebron Hospital Campus, Barcelona.
- Vall d'Hebron Institute of Oncology, Barcelona.
- National Cancer Center Hospital East, Kashiwa, Japan.
- Beijing Cancer Hospital, Beijing.
- Veneto Institute of Oncology, IRCCS, Padua, Italy.
- University Hospitals Gasthuisberg Leuven, Leuven, Belgium.
ORCID-Profile: Jayesh Desai, Scott Kopetz
Förderung
- NCI NIH HHS
- NIH HHS
- Pfizer, Inc.
- Clinical Center
Zitieren
APA
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Morris, V. K., Wu, C., Usari, T., Laliberte, R., Dychter, S. S., Zhang, X., Tabernero, J., …, & BREAKWATER Trial Investigators (2025). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine, 392(24), 2425-2437. https://doi.org/10.1056/nejmoa2501912
Vancouver
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine. 2025;392(24):2425-2437. doi:10.1056/nejmoa2501912
BibTeX
@article{Elez2025,
author = {Elez, Elena and Yoshino, Takayuki and Shen, Lin and Lonardi, Sara and Van Cutsem, Eric and Eng, Cathy and Kim, Tae Won and Wasan, Harpreet Singh and Desai, Jayesh and Ciardiello, Fortunato and Yaeger, Rona and Maughan, Timothy S and Morris, Van K and Wu, Christina and Usari, Tiziana and Laliberte, Robert and Dychter, Samuel S and Zhang, Xiaosong and Tabernero, Josep and Kopetz, Scott and BREAKWATER Trial Investigators, BREAKWATER Trial Investigators},
title = {Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {24},
pages = {2425--2437},
doi = {10.1056/nejmoa2501912}
}
EUVIMED